RecruitingPhase 2NCT07557446
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta
Sponsor
Angitia Biopharmaceuticals Guangzhou Limited
Enrollment
48 participants
Start Date
Jun 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
Eligibility
Min Age: 12 YearsMax Age: 75 Years
Inclusion Criteria3
- Adults (18-75 years) or adolescents (12-17 years) with a confirmed diagnosis of Osteogenesis Imperfecta (OI) Type I, III, or IV with genetic confirmation of pathogenic variants in COL1A1 or COL1A2 genes
- BMD T-score of ≤-1.0 at the lumbar spine, total hip, or femoral neck (adults) or BMD Z-score of ≤-1.0 at the lumbar spine, total hip, or femoral neck (adolescents)
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Exclusion Criteria11
- Vitamin D deficiency
- Concomitant uncontrolled diseases or conditions that could affect bone metabolism such as hypo-/hyperparathyroidism, hypo-/hyperthyroidism, abnormal thyroid function or thyroid disease, or other endocrine disorders.
- Current hyper- or hypocalcemia.
- History of rickets, osteomalacia, or other significant skeletal disorders (excluding OI) leading to long-bone deformities and/or increased risk of fractures.
- Use of bisphosphonates within the past 6 months.
- Use of teriparatide, abaloparatide, strontium ranelate, or hormone replacement therapy within the past 12 months.
- Use of denosumab (or denosumab biosimilars) within the past 2 years.
- Use of anti-sclerostin antibody medications (romosozumab, setrusumab, blosozumab) at any time.
- History of myocardial infarction or stroke (or other cardiovascular associated event deemed significant) within the past 12 months.
- Malignancy within the last 5 years.
- Pregnant or breastfeeding women, or women planning to become pregnant during the study or within 4 months after the last dose of IP.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAGA2115
Participants will receive AGA2115 administered by subcutaneous injection
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07557446